Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-17T02:31:28.461Z Has data issue: false hasContentIssue false
  • English
  • Français

The onset, course and resolution of depressive symptomatology in chronic hepatitis C patients on pegylated interferon alpha: A 72-week prospective study

Published online by Cambridge University Press:  23 March 2020

Z. Pavlovic ,
M. Jasovic-Gasic ,
D. Delic ,
N. Maric ,
O. Vukovic ,
S. Pejovic ,
M. Mihaljevic ,
S. Andric  and
M. Jovicic
Z. Pavlovic
Affiliation:
Clinic for Psychiatry Clinical Centre of Serbia, School of Medicine- University of Belgrade, Belgrade, Serbia
M. Jasovic-Gasic
Affiliation:
University of Belgrade, School of Medicine, Belgrade, Serbia
D. Delic
Affiliation:
3Institute of Infectious and Tropical Diseases,Prof. Dr. Kosta Todorović, Clinical Center of Serbia, Belgrade- Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia
N. Maric
Affiliation:
Clinic for Psychiatry Clinical Centre of Serbia, School of Medicine- University of Belgrade, Belgrade, Serbia
O. Vukovic
Affiliation:
Institut of Mental Health Belgrade, Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia
S. Pejovic
Affiliation:
Clinic for Psychiatry Clinical Centre of Serbia, School of Medicine, Univeristy of Belgrade, Belgrade, Serbia
M. Mihaljevic
Affiliation:
Clinic for Psychiatry Clinical Centre of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia
S. Andric
Affiliation:
Clinical Centre of Serbia, Clinic for Psychiatry, Belgrade, Serbia
M. Jovicic
Affiliation:
Clinical Centre of Serbia, Clinic for Psychiatry, Belgrade, Serbia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Treatment with pegylated interferon alpha (PEG-IFN-α) in patients with chronic hepatitis C (CHC) is associated with depressive symptomatology more frequently than other inflammatory diseases treated with PEG-IFN-α.

Objectives

To prospectively evaluate the onset, course and resolution of depressive symptomatology in CHC patients treated with PEG-IFN-α.

Methods

Hamilton depression rating scale (HAMD) was used to asses depressive symptoms in 103 subjects with CHC prior to initiation of PEG-IFN-α (mean dose 152.6 ± 25.6 mcg; duration of therapy 48 weeks) and at the follow-up visits (4th, 12th, 24th, 48th and 72th week). Control group consisted of 103 CHC subjects, without PEG-IFN-α.

Results

Our results showed a significant increase in HAMD scores as early as in the 4th week of PEG-IFN-a therapy compared to HAMD scores prior to initiation of PEG-IFN-α (38.8% vs. 24.3%). The peak of depressive symptomatology was evidenced in the 12th week (mean HAMD 9.34 ± 6.93), when almost 50% of patients had HAMD above 7. At the end of the treatment (48th week), 38.8% had HAMD above 7, and in the 72nd week (24 weeks after the therapy completion) prevalence of depression was decreased to the values lower than at baseline (23.3% vs. 24.3%). No change in prevalence of depression was detected in control group.

Conclusion

Our results are important because they show the overall course of depressive symptomatology during the interferon therapy. These data also show spontaneously resolution of depression 6 months after the completion of PEG-IFN-α. This study is the longest study in this area.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster viewing: Cultural psychiatry
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S537
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.